Yeragani V K
Wayne State University, School of Medicine, Detroit, Michigan.
Can J Psychiatry. 1990 Mar;35(2):128-32. doi: 10.1177/070674379003500204.
Studies on dexamethasone suppression test (DST) and schizophrenia are reviewed and the incidence of nonsuppression in the group of studies on schizophrenic patients is compared to that in the group of studies on normal controls from a previous review article. The incidence of nonsuppression in schizophrenic patients (26.4%) is significantly higher than that in normal controls (5.0%). There may be a subgroup of schizophrenic patients with an increase in cholinergic functioning. The variance of the nonsuppression rates of DST were also significantly higher in patients with schizophrenia compared to normal controls. This may be due to a heterogeneity of mechanisms that is responsible for the DST non-suppression due to the heterogeneous nature of the diagnosis of schizophrenia. The possible mechanisms of abnormal and varied DST results in schizophrenia are discussed.